Home

Featured

Mind Medicine (MMED.E) gathers people willing to try ibogaine for science

March 25, 2020 by Joseph Mortonibogaine

Mind Medicine (MMED.E) started enrolling candidates for further human safety trial studies of 18-MC, the company’s orally taken ibogaine derivative for the treatment of opioid addiction.

Champignon Brands (SHRM.C) acquires a craft mushroom cultivator, and gives taste-tests in Toronto

March 18, 2020 by Joseph Mortoncraft mushroom

Champignon Brands (SHRM.C) announced their acquisition of British Columbia-based craft mushroom cultivator and supplier Artisan Growers earlier this week.

Captiva Verde (PWR.C): If Canadian shrooms aren’t legal, do business in Mexico

January 21, 2020 by Chris Parry

As we wait for the Canadian courts to repeat the process that made cannabis legal after decades in purgatory, some companies aren’t waiting around for their chance to claim a piece of the upcoming shroomaceuticals market.


Latest

Captiva Verde (PWR.C): If Canadian shrooms aren’t legal, do business in Mexico

January 21, 2020 by Chris Parry

As we wait for the Canadian courts to repeat the process that made cannabis legal after decades in purgatory, some companies aren’t waiting around for their chance to claim a piece of the upcoming shroomaceuticals market.

Yield Growth Corp (BOSS.C) subsidiary takes on 18% of shroom clinical trial outfit

January 21, 2020 by Chris Parry

CBD product developer/retailer Yield Growth Corp (BOSS.C) has announced it has agreed to acquire 18% of Translational Life Sciences, a company that “aims to develop proprietary formulations using restricted substances to focus on unmet medical needs in opioid dependence, psychotic illness, pain management and traumatic brain injury, including concussion.”

Absolem: Laying the groundwork for the big mushroom shift to come

December 8, 2019 by Chris Parry

50 years I’ve been bumbling around this planet, and the best damn weekend I’ve had on it to date occurred recently, under the influence of mushrooms.

Absolem Health signs a mushroom extraction deal

November 27, 2019 by Lukas Kane

On November 26, 2019  Absolem Health announced that it has entered into an L.O.I with Arev Brands (AREV.C) to “develop and produce mushroom extracts”, and potentially to collaborate to sell “mushroom-based products.”

How MAPS broke from the pack of profit-oriented psychedelic industry

November 19, 2019 by Ethan ReyesMAPS, Doblin, COMPASS Pathways, Mental illness, PTSD

With a stated mission of patients over profits, the Multidisciplinary Association for Psychedelic Studies (MAPS) is an outlier within the growing psychedelic treatment industry.

Mushrooms may be key to answering “100–110% increase in global crop demand” by 2050

October 21, 2019 by Ethan Reyescrop, ThinkMyco, sustainability, agriculture, global warming, fungi, protein

A 2015 study found by 2050, Earth will need to increase crop yields by between 60% and 110% to sustain a rapidly expanding human populace.

We downloaded RLOVE, a dating app for psychonauts and “light warriors.” Here’s what happened

October 16, 2019 by Ethan Reyesdating app, Match Group, psychedelic, Tinder, RLAC, RLOVE

RLOVE is a new dating app designed “to connect awakened souls” who aren’t able to find partners through more traditional, tried and true means such as OkCupid.

Salvation Labs is growing a psychedelic division with cash from recreational cannabis sales

October 1, 2019 by Ethan Reyescannabis, Numinus, SLAB, salvation botanicals, salvation labs, michael tan, numinus, Nyquvest, Universal Ibogaine, psychedelic treatment

When walking through the woods, or even a particularly grassy side street, it is not uncommon to see mushrooms of the same variety sprouting up through the undergrowth.

RethinkX, the end of beef and how to eat our way out of climate change

September 30, 2019 by Ethan Reyesprotein, rethinkx, thinkmyco, Nikita, BYND.Q, Beyond Meat, sustainability, climate change

RethinkX, a think tank which analyzes industry-disrupting technologies, has published a report about new sources of protein at a time when hamburgers may be costlier than advertised.

A Closer Look: ThinkMyco pushes the button on magic mushroom market

September 26, 2019 by Ethan Reyesthinkmyco, psilocybin

Psilocybin and other psychedelics are forcing their way out of prohibition as potentially viable treatments for not only depression and anxiety but also Alzheimer’s and other neurodegenerative diseases plaguing millions in North America alone. In the end, psilocybin solutions address a $300 billion dollar psychotherapy and wellness global market.

Roadman Investments (LITT.V) Amsterdam JV brings home Psychedelic Insights

February 6, 2020 by Joseph Mortonpsychedelic

Roadman Investments (LITT.V) is forming a California-based joint-venture with lifestyle centre Psychedelic Insights to open the first psilocybin therapy centre in the United States when the states get around to legalizing it.

The City of Santa Cruz joins the shroom-boom

January 30, 2020 by Joseph Mortonshroom-boom

The shroom-boom continues to develop as the City of Santa Cruz is the latest to decriminalize magic mushrooms.

Graph Blockchain’s (GBLC.C) latest shroom-venture shows they’re not willing to raise the white flag yet

January 24, 2020 by Joseph Morton

Graph Blockchain’s (GBLC.C) story is either going to be one of ultimate failure—an object lesson of what not to do for new companies—or an absolutely great comeback story, but what’s obvious is that they’re not willing to fly the white flag anytime soon.

Yield Growth (BOSS.C) subsidiary Flourish Mushrooms forms JV to do research and development in paradise

January 7, 2020 by Joseph MortonFlourish

Flourish Mushroom Labs, a subsidiary of Yield Growth (BOSS.C), entered into a binding letter of intent with Acres Agricultural Canada to form a JV in Saint Vincent and the Grenadines for the cultivation of psilocybin mushrooms, and for research and development into compounds and therapeutic uses for psychedelic mushrooms.